# A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

> **NCT00171704** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 263 (actual)

## Conditions studied

- Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00171704
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2017-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171704, "A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00171704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*